Recent Press Releases

AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business

Acquisition to include non-US rights to roflumilast and will be accretive to 2016 earnings, contributing to AstraZeneca's return to growth strategy 16 December 2015 AstraZeneca today announced...

Cummings Demands Documents and Interviews From Valeant Ahead of Oversight Hearing

Washington, DC (Dec. 16, 2015)—In advance of an upcoming hearing before the House Committee on Oversight and Government Reform, Ranking Member Elijah E. Cummings sent a letter to J. Michael...

ASTRAZENECA CONTINUES STRATEGIC INVESTMENT IN CHINA TO ACCELERATE DELIVERY OF INNOVATIVE BIOLOGICS AND TARGETED MEDICINES

Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development 16 December 2015 AstraZeneca,...

Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems

15 December 2015 Issued: London A five-year partnership to fight malaria and improve health in five countries worst affected by the disease has today been launched by Comic Relief and GSK. The two...

Amgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries

Adds Product Rights and Sales in Key Global Expansion Countries THOUSAND OAKS, Calif., Dec. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive...

Pacira Pharmaceuticals Announces Favorable Resolution with U.S. Food and Drug Administration, which Reaffirms the Broad Indication for EXPAREL®

-- Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Rescission of 2014 Warning Letter – -- Conference Call...

Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory...

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Animal Health Company

Paris and Ingelheim - December 15, 2015 - Sanofi and Boehringer Ingelheim today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction...

FDA grants Roche's Alecensa (alectinib) accelerated approval for people with a specific type of lung cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) granted accelerated approval to Alecensa® (alectinib) for the treatment of people with anaplastic...

NICE gives green light to innovative drug for common heart condition

In draft guidance published today for consultation, NICE has provisionally recommended novel heart failure drug sacubitril valsartan (Novartis) as an option for some people with heart failure....

NICE publishes draft guidance on two prostate cancer treatments

NICE has issued draft guidance for enzalutamide and abiraterone as treatment options for prostate cancer. NICE has issued final draft guidance recommending enzalutamide (marketed as Xtandi by...

Horizon Pharma plc to Acquire Crealta Holdings LLC in All Cash Acquisition

Addition of Biologic KRYSTEXXA(R) (pegloticase) Expands and Diversifies Horizon's Orphan Business; Leverages Rheumatology Expertise and Infrastructure; Transaction Is Expected to Be Immediately...

Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access TARRYTOWN, N.Y. and BRIDGEWATER, N.J, Dec. 11, 2015 /PRNewswire/ -- Regeneron...

McCaskill: 'The Facts Underlying This Hearing Are So Egregious, It's Hard Not to Get Emotional About It'

McCaskill: 'The Facts Underlying This Hearing Are So Egregious, It's Hard Not to Get Emotional About It' Senator tackles price spikes in Rx drugs in first bipartisan Senate hearing on the issue in...

Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII

Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII Extended-Release Is Now Chewable: First and Only...

SANDOZ ADVANCES ITS BIOSIMILARS PROGRAM WITH EUROPEAN MEDICINES AGENCY (EMA) ACCEPTANCE OF REGULATORY SUBMISSION FOR BIOSIMILAR ETANERCEPT

Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes that...

CSL Behring Expands Operations to Russia

CSL Behring Expands Operations to Russia Moscow opening reinforces CSL Behring's promise to deliver its world-class therapies to patients with rare and serious diseases around the world. KING...

Daiichi Sankyo Announces Reorganization of its Research & Development Structure

For Immediate Release 2015.12.01 Daiichi Sankyo Announces Reorganization of its Research & Development Structure Tokyo, Japan (December 1, 2015) - Daiichi Sankyo Company, Limited (Chuo-Ku, Tokyo;...

POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals

-US$350 Million Capital Commitment from Deerfield-Led Syndicate- -Canada Domicile Provides Similar Competitive Structure and Benefits to Ireland- -Previously Scheduled Shareholder Meetings of POZEN...

IBRUTINIB (IMBRUVICA®) IMPROVES SURVIVAL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN THE PHASE 3 RESONATE™-2 TRIAL

NORTH CHICAGO, Ill., Dec. 6, 2015 /PRNewswire/ -- Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in...